Positive FDA Update on Elanco’s Zenrelia Supports Buy Rating

Elanco Animal Health, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Ryskin from Bank of America Securities maintained a Buy rating on the stock and has a $21.00 price target.

Michael Ryskin’s rating is based on the recent positive update to Elanco Animal Health’s Zenrelia product label. The FDA has approved a change that removes the “fatal vaccine-induced disease” warning, which reflects additional clinical data submitted by Elanco. This update is seen as a step forward, although the label still advises discontinuation of use around vaccination periods to address safety concerns.
Despite the remaining cautionary language, Ryskin maintains a Buy rating due to Elanco’s ongoing commitment to innovation and new product development. The company is well-positioned in the market, and the recent label update is a positive indicator of its progress. Elanco’s efforts to further improve the Zenrelia label and its overall product portfolio support the Buy recommendation.

In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $23.00 price target.